Hyperthermia has been shown to be a potential purging modality in autologous stem cell transplantation settings owing to its selective toxicity towards leukaemic cells, We describe two approaches to further increase the therapeutic index of the hyperthermic purging modality by using normal murine bone marrow cells and a murine model for acute myeloid leukaemia. First, the tetrapeptide AcSDKP was used to protect the normal haematopoietic progenitor cells against hyperthermic damage, Pretreatment for 8 h at 37 degreesC with 1 x 10(-9) mol/l AcSDKP resulted in a decrease in hyperthermic sensitivity of only normal haematopoietic progenitor cells, This combined treatment protocol revealed a therapeutic index (ratio of surviving fractions of normal vs, leukaemic cells) of > 500, which was considered to be sufficient fur purging. This was confirmed in vivo by the survival of lethally irradiated recipients transplanted with purged simulated remission bone marrow (1 x 10(6) normal bone marrow cells and 5 x 10(4) leukaemic cells). A further increase of the therapeutic index cells was achieved by the alkyl-lysophospholipid ET-18-OCH3. An incubation for 4 h at 37 degreesC with 25 mug/ml in the presence of 5% fetal calf serum preferentially enhanced the cytotoxic effect towards the leukaemic stem cell. The combination of AcSDKP and ET-18-OCH3 with hyperthermia resulted in a therapeutic index of > 5000. This enabled a reduction of the hyperthermic treatment and will further minimize the toxicity to normal haematopoietic stem cell subsets, while a therapeutic index far above the required Value is achieved. This tripartite purging treatment therefore offers a safe and East purging protocol for the elimination of residual leukaemic cells in autografts.
|Number of pages||8|
|Journal||British Journal of Haematology|
|Publication status||Published - Dec-2000|
- BONE-MARROW TRANSPLANTATION
- AUTOLOGOUS MARROW
- PROGENITOR CELLS
- ETHER LIPIDS